MSP Recovery (NASDAQ:MSPR – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Profitability
This table compares MSP Recovery and SOPHiA GENETICS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MSP Recovery | -7,328.48% | -326.80% | -81.27% |
| SOPHiA GENETICS | -41.13% | -37.75% | -18.75% |
Risk & Volatility
MSP Recovery has a beta of -2.93, meaning that its stock price is 393% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MSP Recovery | 1 | 0 | 0 | 0 | 1.00 |
| SOPHiA GENETICS | 1 | 0 | 1 | 0 | 2.00 |
SOPHiA GENETICS has a consensus price target of $7.00, suggesting a potential upside of 28.44%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than MSP Recovery.
Institutional and Insider Ownership
3.8% of MSP Recovery shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 50.5% of MSP Recovery shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares MSP Recovery and SOPHiA GENETICS”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MSP Recovery | $9.81 million | 0.10 | -$360.50 million | ($572.83) | 0.00 |
| SOPHiA GENETICS | $65.17 million | 5.65 | -$62.49 million | ($0.46) | -11.85 |
SOPHiA GENETICS has higher revenue and earnings than MSP Recovery. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.
Summary
SOPHiA GENETICS beats MSP Recovery on 12 of the 14 factors compared between the two stocks.
About MSP Recovery
MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for MSP Recovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MSP Recovery and related companies with MarketBeat.com's FREE daily email newsletter.
